CING Cingulate Inc.

Biotech Analyst Ratings

Latest News

1. 12 May 2022 Cingulate Inc. Reports First Quarter 2022 Results and Provides Clinical and Business Update

   KANSAS CITY, Kan., May 12, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three months ended March 31, 2022, and provided a clinical and business update, which includes the announcement of first subject dosing in its human formulation study of CTx-2103 (buspirone) for the treatment of anxiety.
   

   "At its core, Cingulate has maintained a primary focus on addressing patients' suboptimal treatment outcomes and overcoming unmet needs due to the limitations of current standard of care treatments…

   View Full Article
2. 26 April 2022 Cingulate Presents at NobleCon18

   KANSAS CITY, Kan., April 26, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that its Chairman and Chief Executive Officer, Shane J. Schaffer, recently presented a company overview at NobleCon18 - Noble Capital Markets' Eighteenth Annual Investor Conference at the Hard Rock Hotel & Casino, Hollywood, Florida.
   

   A video webcast of the April 20 presentation may now be accessed on the company's website at www.cingulate.com/investors, and as part of a complete catalog of presentations available at Noble Capital Markets…

   View Full Article
3. 10 March 2022 Cingulate Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Clinical and Business Update

   Completed Initial Public Offering, Raising Gross Proceeds of $25.0 Million
   

   Expedited Clinical Program for CTx-1301 Expected to Reduce Capital Requirements and Time to Approval

   KANSAS CITY, Kan., March 10, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three and 12 months ended December 31, 2021, and provided a clinical and business update.

   "Our recent initial public offering was a significant milestone for Cingulate in advancing our mission to help Attention Deficit/Hyperactivity…

   View Full Article
4. 15 February 2022 Cingulate to Present at Aegis Virtual Conference

   KANSAS CITY, Kan., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Shane J. Schaffer, Chairman and Chief Executive Officer, will present a company overview at the Aegis Capital Corp. Virtual Conference on February 24, 2022, at 10:30 a.m. ET.
   

   Cingulate's presentation will be available by request to Aegis for the duration of the conference, from February 23 through February 25.

   To access the event, you may download and import the following iCalendar (.ics) files to your calendar system: Aegis Virtual …

   View Full Article
5. 08 February 2022 Cingulate Provides 2022 Clinical Plan for CTx-1301, an Investigational Medication for Attention Deficit/Hyperactivity Disorder (ADHD)

   KANSAS CITY, Kan., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced updates to its 2022 clinical program for its lead candidate CTx-1301, an investigational asset for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).
   

   This year, the Company plans to initiate its CTx-1301 Phase 3 clinical studies: a fixed-dose pediatric and adolescent safety and efficacy study, a dose-optimization study extension, and a pediatric safety and efficacy study to assess the onset and duration of efficacy. Specifically…

   View Full Article